Blog

Wugen is a US-born and based biotech that develops off-the-shelf allogeneic CAR-T therapies to treat hematological malignancies. In particular, Wugen has taken on the very difficult challenge of treating T-cell malignancies, which are notoriously complicated to target with immunotherapy due to two main challenges (1): Fratricide or friendly fire (CAR-T vs CAR-T): CAR-T cells themselves […]

Kite (a @Gilead company) announced the complete buyout of Interius BioTherapeutics, a biotech company developing in vivo CAR-T and NK cell reprogramming platforms, for $350 million USD in cash.

Last June, Abbvie confirmed the acquisition of Capstan Therapeutics for 2.1bn USD cash. Given the recent amount and volume of biotech M&As, this might not be surprising.    However, the interesting aspect of this deal is the drug pipeline of Capstan Therapeutics: at the moment, none of their therapies is currently in late clinical testing;

Have a look at how a german Biotech company has leveraged the poisonous Amanitin compound to develop anti-cancer therapies.

As the FDA begins phasing out animal testing requirements for monoclonal antibody development, new human-relevant technologies are taking the spotlight. This post explores the cutting-edge tools reshaping early drug discovery—and what this shift could mean for the future of therapeutics.